| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.53(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,425 |
| 52
Week Range: |
$120.4 - $284.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.9 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
136,370 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$30,065,193 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
10 |
10 |
| Total Shares Sold |
276,067 |
293,667 |
293,667 |
363,156 |
| Total Sell Value |
$67,426,178 |
$71,246,652 |
$71,246,652 |
$90,715,080 |
| Total People Sold |
7 |
8 |
8 |
9 |
| Total Sell Transactions |
15 |
23 |
23 |
28 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gollust Keith R |
Director |
– • – |
2007-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,819 |
39,176 |
|
- |
|
| Reardon William S |
Director |
– • – |
2007-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,204 |
2,826 |
|
- |
|
| Wilson Robert N |
Director |
– • – |
2007-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,819 |
350,876 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2007-06-11 |
4 |
B |
$8.56 |
$296,903 |
D/D |
34,600 |
902,069 |
3.92 |
- |
|
| Kovner Bruce |
Director |
– • • |
2007-06-08 |
4 |
B |
$8.28 |
$297,473 |
D/D |
35,867 |
867,469 |
3.92 |
- |
|
| Williams Martin D |
Sr. VP, Business Dev., CBO |
• – – |
2007-02-09 |
4 |
B |
$10.00 |
$2,000 |
D/D |
200 |
200 |
2.66 |
- |
|
| Jacobson Eric W |
Sr. VP, Research and CMO |
• – – |
2007-02-09 |
4 |
B |
$10.00 |
$3,000 |
D/D |
300 |
25,300 |
2.66 |
- |
|
| Caxton Corp |
10% Owner |
– – • |
2007-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,690,646 |
7,761,716 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2007-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,690,646 |
7,761,716 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2007-02-09 |
4 |
B |
$10.00 |
$7,200,000 |
D/D |
720,000 |
831,602 |
3.92 |
- |
|
| Kovner Bruce |
Director |
– • • |
2007-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
23,648 |
111,602 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2007-02-09 |
4 |
B |
$10.00 |
$1,800,000 |
I/I |
180,000 |
1,330,970 |
2.1 |
- |
|
| Gollust Keith R |
Director |
– • – |
2007-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
235,454 |
1,150,970 |
|
- |
|
| Wilson Robert N |
Director |
– • – |
2007-02-09 |
4 |
B |
$10.00 |
$1,000,000 |
D/D |
100,000 |
346,057 |
2.39 |
- |
|
| Wilson Robert N |
Director |
– • – |
2007-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
52,973 |
246,057 |
|
- |
|
| Rieder Wendy E |
VP, IP and Legal, Gen. Counsel |
• – – |
2007-02-05 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
20,426 |
|
- |
|
| Koya Keizo |
Sr. VP, Drug DevelopmentOffice |
• – – |
2007-02-05 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
33,045 |
|
- |
|
| Ehrlich Keith S |
VP, Fin. and Admin., CFOOffice |
• – – |
2007-02-05 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
20,426 |
|
- |
|
| Chadwick Jeremy G |
Sr. VP, Pgm Mgmt and Clin OpsO |
• – – |
2007-02-05 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
20,426 |
|
- |
|
| Wilson Robert N |
Director |
– • – |
2007-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
193,084 |
|
- |
|
| Caxton Corp |
10% Owner |
– – • |
2007-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,071,070 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2007-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,071,070 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2007-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
87,954 |
|
- |
|
| Bahcall Safi R |
President and CEOOfficer |
• • – |
2007-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
110,000 |
|
- |
|
| Bahcall Safi R |
President and CEOOfficer |
• • – |
2007-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,245,525 |
|
- |
|
416 Records found
|
|
Page 16 of 17 |
|
|
5.27 (2.24%) 
